SSA-MOA: a novel CTC isolation platform using selective size amplification (SSA) and a multi-obstacle architecture...

Area of Science:

• Biotechnology
• Cancer Research
• Medical Diagnostics

Background:

• Circulating tumor cells (CTCs) are crucial in understanding metastatic cancer.
• Current CTC isolation methods face challenges with recovery rates, purity, and cell stress.
• Robust and reproducible CTC isolation is vital for clinical applications.

Purpose of the Study:

• To develop a novel CTC isolation technology addressing the trade-off between recovery and purity.
• To minimize cell deformation and stress during CTC isolation.
• To enhance the sensitivity and reliability of CTC detection for clinical use.

Main Methods:

• Utilized selective size amplification (SSA) with anti-EpCAM microbeads to amplify target CTCs.
• Employed a novel multi-obstacle architecture (MOA) filter fabricated with silicon-on-glass (SOG) technology.
• Investigated optimal microbead diameter (3 μm) for size discrimination and surface coverage.

Main Results:

• Achieved a 92% average CTC recovery rate with high purity.
• Demonstrated reduced cell deformation and stress using the MOA filter compared to single-obstacle designs.
• Successfully differentiated CTCs from white blood cells (WBCs) by avoiding size overlap.

Conclusions:

• The SSA-MOA platform offers improved CTC recovery, purity, and stability.
• This technology has the potential to increase the sensitivity and reliability of CTC detection assays.
• The developed SSA-MOA system is expected to expand the clinical utility of CTC technologies.